Abstract: A self-expanding metallic stent (SEMS) has drug-encapsulated polymeric yarns intertwined with stent struts at specific locations along a length of the stent. The polymeric yarns in one instance comprise microfibers.

Abstract: There is provided herein methods generating a population of primed mesenchymal stem cell-derived exosomes. A method in accordance with the disclosure may comprise expanding a population of mesenchymal stem cells (MSCs) in culture, administering one or more priming agents in the culture to prime the population of MSCs and obtain a population of primed MSCs: growing the population of die primed MCSs in culture to produce a primed-MSC-derived conditioned medium; collecting the primed MSC-conditioned medium; and purifying a population of exosomes from the primed MSC-conditioned medium. The one or more priming p agents may comprise a conditioned media derived from a population of stem cells different from the population of MSCs, a Nrf2 activator, or a combination thereof. There is also provided herein methods of treating tissues such as cornea and liver using the population of exosomes from the primed MSC-conditioned medium.

Abstract: The present disclosure discloses methods for culturing stem cells in three-dimensional methods. Said method is either a spheroid-based method or a microcarrier-based method. The process as described herein leads to the expansion of the stem cells to obtain an expanded population of the stem cells, and a stem cell derived-conditioned medium. The present disclosure also discloses an expanded population of the stem cells, and a stem cell derived-conditioned medium obtained from the process as described herein. Further, an exosome preparation obtained from the stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the stem cells, or a stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof. Methods of treatment using the composition as described herein is also disclosed in the present disclosure.

Abstract: The present disclosure discloses a xeno-free bio-ink formulation amenable to be printed using a 3D printer. The bio-ink formulation exhibits optimum viscosity in the range of 1690-5300 cP. The present disclosure discloses a bio-printed corneal lenticule obtained from the bio-ink formulation. The bio-printed corneal lenticule as disclosed is of the optimum thickness in the range of 10-500 microns and exhibits transmittance in the range of 80-99%. The present disclosure also discloses a process for preparing the bio-ink formulation as well as for preparing the bio-printed corneal lenticule. Further, the present disclosure discloses a method of treating a corneal defect using the bio-printed corneal lenticule as an implant to treat the corneal defect. The bio-printed corneal lenticule can further be used as a model for in-vitro drug testing and diseases modelling.

Abstract: The present disclosure discloses a bioengineered formulation comprising: (a) a modified collagen peptide having a molecular weight in the range of 20-80 kDa, and with a degree of substitution in the range of 20-75%; and (b) a modified hyaluronic acid having a molecular weight in the range of 10-100 kDa, and with a degree of substitution in the range of 20-75%. The present disclosure also discloses the bioengineered formulation comprising stem cells, or exosomes, or combinations thereof. Further, the process for preparing the bioengineered formulation is also disclosed therein. Moreover, the formulation comprising: a) exosomes selected from the group consisting of corneal stromal stem cell derived-exosomes, primed mesenchymal stem cell derived-exosomes, and naive mesenchymal stem cell derived-exosomes; and (b) a clinically approved eye drop formulation is also provided.

Abstract: The present disclosure discloses embodiments of a formulation for application to the cornea, the formulation comprising a hyaluronic acid, a gelatin, and exosomes. In certain variations, the exosomes may be naive mesenchymal stem cell-derived exosomes, primed mesenchymal stem cell derived-exosomes, or corneal stromal stem cell derived-exosomes. In certain variations, the primed mesenchymal stem cell-derived exosomes are exosomes derived from mesenchymal stem cells primed with a corneal stromal stem cell derived-conditioned medium.

Abstract: The present disclosure discloses embodiments of exosome compositions comprising primed mesenchymal stem cell-derived exosomes.

Abstract: The present disclosure provides a process for obtaining an expanded primed mesenchymal stem cell population. In the process, the MSCs are cultured in the culture medium comprising a corneal stromal stem cell derived-conditioned medium to obtain the expanded population of the primed mesenchymal stem cell population along with the mesenchymal stem cell derived-conditioned medium. Also, provided is a method of culturing the MSCs in 3D culture using a spheroid-based method or a microcarrier-based method, in order to obtain the expanded primed mesenchymal stem cell population. Further, an exosome preparation obtained from the expanded primed mesenchymal stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the primed mesenchymal stem cells, or a primed mesenchymal stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof.

Abstract: Electrospinning apparatus and method for producing multi-dimensional structures such as one-dimensional continuous yarns, two-dimensional mats and three-dimensional cotton-like fluffy scaffolds is disclosed. Further, electrospinning apparatus and method with single collector geometry for producing multi-dimensional structures and core-sheath yarns are disclosed.

Abstract: Electrospinning apparatus and method for producing multi-dimensional structures such as one-dimensional continuous yarns, two-dimensional mats and three-dimensional cotton-like fluffy scaffolds is disclosed. Further, electrospinning apparatus and method with single collector geometry for producing multi-dimensional structures and core-sheath yarns are disclosed.

Abstract: Aporous composite fibrous scaffold for repair or regeneration of bone is disclosed. The scaffold comprises a first biopolymer forming a porous matrix and a second biopolymer forming fiber reinforcement. The biocompatible scaffold is configured to maintain balance between porosity and mechanical strength which could aid cellular infiltration and bone tissue regeneration. A method of preparing the porous composite scaffold is also disclosed.

Abstract: A method and system for multicasting data in a communication network (100) to a specific group of user equipments (UEs) (120) that includes a source UE (102). The method provides for communicating (302) at least one FlowID to the specific group (120), the communicating including informing the specific group (120) of a broadcast server's IP address and port number to allow the UEs to set up resources in the network (100) for reception of wireless multicast data. The method also includes allowing (303) the source UE (102) to have a floor control for the specific group (120) that are uniquely identified in the network (100), the allowing being provided by a push server (112). Next, the method provides for receiving the data (304) at the broadcast server (114), from the source UE (102), and then multi-casting the data in non-duplicated packets to the specific group (120).